Clinical trials · New York
Metastatic Malignant Solid Neoplasm clinical trials in New York
We’re tracking 37 recruiting metastatic malignant solid neoplasm studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Mineola, New YorkAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Brooklyn, New YorkAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Buffalo, New YorkAges Any age - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Mineola, New YorkAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Mineola, New YorkAges 18 years+ - NCT04329494RecruitingPhase 1
Study of targeted drug delivery into the abdomen using PIPAC
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Greenlawn, New YorkAges 18 years+ - NCT04511039RecruitingPhase 1
New targeted pill combo for advanced colon or stomach cancers
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Buffalo, New YorkAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
New York, New YorkAges 12 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
New York, New YorkAges 1–30 - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
New York, New YorkAges 18 years+ - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
New York, New YorkAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Rochester, New YorkAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Brooklyn, New YorkAges 18 years+ - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Brewster, New YorkAges 16 years+ - NCT02474160Recruiting
Banking cancer tissue and blood for future research
This study collects and stores leftover or newly taken samples of tissue and blood from people with cancer. The goal is to build a research library that can help investigators study cancer and develop better tests or treatments.
The Bronx, New YorkAges 2 months+ - NCT06240728RecruitingPhase 1
Testing NPX887 for advanced solid tumors with B7-H7 protein
This trial tests a new drug called NPX887 that targets a protein (B7-H7) on certain cancer cells to help your immune system fight them. It is for people with advanced solid tumors that have not responded to other treatments.
The Bronx, New YorkAges 18 years+ - NCT06295367Recruiting
Cost Communication and Financial Help for Newly Diagnosed Cancer Patients
This study looks at whether talking openly about treatment costs and providing guidance to find financial help can make a difference for people with newly diagnosed solid tumors. If you join, you will be asked to fill out surveys about your experience.
The Bronx, New YorkAges Any age - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Commack, New YorkAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
New York, New YorkAges 1 month–17 years - NCT06979596RecruitingPhase 2
A study of MK-5684 for certain solid tumors
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
New York, New YorkAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Buffalo, New YorkAges 18 years+ - NCT02421380Recruiting
Tests how repeatable a special MRI scan is for tumors
This study checks whether a specialized MRI using injected “hyperpolarized pyruvate” gives consistent tumor images when repeated. It may help future patients by improving how reliably this scan can measure tumors.
New York, New YorkAges 21–90 - NCT07525141RecruitingPhase 1
Testing JNJ-1761981 for advanced solid tumors
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
The Bronx, New YorkAges 18 years+
Metastatic Malignant Solid Neoplasm trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting metastatic malignant solid neoplasm studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Columbia University Irving Medical Center · 8 studies
- NYU Langone Health · 8 studies
- Montefiore Medical Center · 7 studies
- NYU Langone Hospital - Long Island · 6 studies
- Weill Cornell Medicine · 5 studies
- Memorial Sloan Kettering Commack · 4 studies
- Memorial Sloan Kettering Nassau · 4 studies
What taking part in a metastatic malignant solid neoplasm study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Malignant Solid Neoplasm trials in other states
Common questions
- Are there metastatic malignant solid neoplasm clinical trials in New York?
- Yes. We're currently tracking 37 recruiting metastatic malignant solid neoplasm studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic malignant solid neoplasm study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic malignant solid neoplasm trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic malignant solid neoplasm studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.